A Meeting is Held to Require Accelerating the Review and Approval of Drugs and Medical Devices and Solidly Promoting the Implementation and Production of Key Foreign Investment Projects in the Pharmaceutical Industry
In order to thoroughly implement the decisions and arrangements of the CPC Central Committee and the State Council and focus on the new missions and new requirements proposed in the Report to the 20th CPC National Congress, the National Medical Products Administration (“NMPA”) held a working meeting on advancing foreign trade and foreign investment on November 15, 2022, to study and arrange measures to further strengthen services for pharmaceutical industry foreign investment enterprises and ensure service support for key foreign investment projects. Zhao Junning, Member of the CPC Leading Group and Deputy Commissioner of the NMPA attended the meeting and delivered a speech.
According to Zhao Junning, the NMPA pays high attention to services for foreign trade and foreign investment and has successively issued the Notice of the Department of Comprehensive Affairs, Planning, and Finance Affairs of the National Medical Products Administration on Further Strengthening Services for Foreign-Funded Enterprises and the Notice of the Department of Comprehensive Affairs, Planning, and Finance Affairs of the National Medical Products Administration on Establishing the Leading Group for Foreign Trade and Foreign Investment Coordination to comprehensively arrange work for advancing services for foreign trade and foreign investment. Guided by the spirit of the 20th CPC National Congress, the NMPA will make every effort to advance services for foreign trade and foreign investment according to the overall requirements thereof.
Zhao Junning emphasized that local administrations and departments under the NMPA should further increase services for foreign trade and foreign investment, accomplish review, approval and regulation of anti-pandemic drugs and medical devices and, on this basis, accelerate review and approval of other drugs and medical devices, strengthen regulation of the quality of anti-pandemic products and solidly promote the implementation and production of key foreign investment projects in the pharmaceutical industry. Firstly, the implementation of various tasks should continue to be effectively advanced according to the requirements of the notice on strengthening services for foreign-funded enterprises; secondly, the issues and demands of foreign business associations and foreign-funded enterprises in China should be looked into by making full use of the existing communication channels and mechanisms; thirdly, according to the principle of territory, provincial administrations should be guided by the NMPA to ensure service support for key foreign investment projects.
Around local advancement of foreign trade and foreign investment, progress in promoting key foreign investment projects, etc., representatives of the participating provincial administrations exchanged good experience and practices and identified their future work objectives and initiatives.
Related personnel of drug, medical device and cosmetics departments of and entities directly under the NMPA attended the meeting on site, and related responsible persons from 11 administrations in Tianjin, Hebei, Jilin, Shanghai, Jiangsu, Zhejiang, Fujian, Shandong, Henan, Hubei and Guangdong involving key foreign investment projects attended the meeting online via video connections.